Terenius L, Sandin J, Sakurada T
Department of Clinical Neuroscience, Experimental Alcohol and Drug Addiction Research, Karolinska Institutet, CMM L8:01, Karolinska Hospital, S-171 76, Stockholm, Sweden.
Peptides. 2000 Jul;21(7):919-22. doi: 10.1016/s0196-9781(00)00228-x.
The endogenous ligand for the orphan NOR receptor (earlier named ORL1) was recently discovered. This ligand, nociceptin/orphanin FQ is involved in a number of pharmacological actions in the CNS, including modulation of pain and cognition. However, its specific physiological role remains to be determined. Two major pathways of metabolism have been identified; the action of aminopeptidase(s) that prominently occurs in plasma, and endopeptidase activity that successively generates the N-terminal 1-13 and 1-9 fragments. Both pathways result in fragments that are inactive at the NOR receptor. However, short N-terminal fragments appear to be active in blocking the release of substance P from primary afferent C-fiber terminals in the dorsal spinal cord. The same endopeptidase(s) may also be involved in the fragmentation of dynorphin A since the inhibitor profile is similar. Enzyme activity is upregulated by morphine using either peptide as substrate that may lead to pharmacological interactions.
孤儿型阿片受体(之前称为ORL1)的内源性配体最近被发现。这种配体,即孤啡肽/痛敏肽,参与中枢神经系统的多种药理作用,包括疼痛和认知调节。然而,其具体的生理作用仍有待确定。已确定了两条主要的代谢途径;氨基肽酶的作用主要发生在血浆中,以及内肽酶活性,其依次产生N端1 - 13和1 - 9片段。两条途径都会产生在阿片受体处无活性的片段。然而,短的N端片段似乎在阻断背脊髓初级传入C纤维终末中P物质的释放方面具有活性。由于抑制剂谱相似,相同的内肽酶也可能参与强啡肽A的片段化。以任一肽为底物时,吗啡都会上调酶活性,这可能导致药理相互作用。